Hereditary Risk Factors for Thyroid Cancer

Thyroid Cancer Clinical Trial

Official title:

Hereditary Risk Factors for Thyroid Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02747888
• Other study ID #: 15-159
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2016
• Est. completion date: March 1, 2029

Study information

• Verified date: April 2024
• Source: Dana-Farber Cancer Institute
• Contact: Junne Kamihara, MD, PhD
• Phone: 617.632.3044
• Email: junne_kamihara[@]dfci.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Thyroid cancers can occur sporadically, but can also be found as tumors that cluster in families with other cancers or genetic syndromes. Researchers are studying thyroid cancer in children and families, with a particular interest in understanding genes and other factors that may put individuals at risk for developing thyroid cancer and thyroid nodules.

• In this study, family and medical history information is collected alongside a blood or saliva sample for genetic studies.

• Individuals with a past or present childhood thyroid cancer/nodule or a thyroid cancer suspected to be inherited in their family are invited to participate.

Description:

The purpose of this research study is to learn more about risk factors for inherited thyroid cancer.

The investigators would like to use the participant DNA to look for alterations in genes. The investigator will perform DNA sequencing and other genetic studies to identify errors in the genes that may contribute to the formation of thyroid nodules and cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 250
• Est. completion date: March 1, 2029
• Est. primary completion date: March 1, 2029
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Individual pediatric patient with current or previous known or suspected thyroid cancer or nodule(s).

• Individual adult patient with current or previous known or suspected thyroid cancer or nodule(s) if they come from a family with a high suspicion of hereditary cancer (as below).

• Individuals from families with a high suspicion of hereditary thyroid cancer:

• Families with a current or previous diagnosis of a thyroid cancer/nodule occurring in childhood (<18 years old).

• Families with a high suspicion of hereditary thyroid cancer/nodules other than above to include:

• Families with thyroid cancer in multiple individuals

• Families with thyroid cancer and a known genetic syndrome

• Families with thyroid cancer and a suspected genetic syndrome (e.g. multiple childhood cancers in the family, multiple primary cancers, multiple endocrinopathies, etc.)

Exclusion Criteria:

• Individuals who are unable to give informed consent.

• Individuals who are unable to complete study materials.

Related Conditions & MeSH terms

• Thyroid Cancer
• Thyroid Diseases
• Thyroid Neoplasms

Intervention

Genetic:
• •Referral to Genetic Counselor, if indicated

Locations

Country	Name	City	State
United States	Dana Farber Cancer Institute	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants who have childhood or suspected familial thyroid nodules/cancer		2 years
Primary	Number of germline mutations identified associated with thyroid cancer predisposition		2 years
Primary	Prevalence of suspected familial thyroid cancer among those with childhood thyroid nodules/cancer		2 years